Biotech: Stubbornly Unconsolidated
Executive Summary
A few 1994-95 biotech acquisitions seemed to hint at the always tantalizing possibility that Big Pharma would pay handsomely for biotech's innovation by buying the companies.But buying drug related biotech stocks in the hopes of high-value acquisitions looks a lot like Lotto odds.